Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
This announcement reiterates the securities class action related to Ultragenyx’s prior setrusumab Ph...
Analysis
This announcement reiterates the securities class action related to Ultragenyx’s prior setrusumab Phase 3 failures, highlighting alleged losses between August 3, 2023 and December 26, 2025 and an April 6, 2026 lead-plaintiff deadline. It references the earlier ~42% share-price drop from $34.19 to $19.72. Investors can contextualize this legal backdrop alongside recent clinical progress and governance disclosures when assessing overall risk exposure.
Key Figures
Class period start:August 3, 2023Class period end:December 26, 2025Share price drop:42%+5 more
8 metrics
Class period startAugust 3, 2023Alleged securities fraud period start for class action
Class period endDecember 26, 2025Alleged securities fraud period end for class action
Share price drop42%Decline after setrusumab Phase 3 failures, Dec 26–29, 2025
Price before drop$34.19Ultragenyx share price on Dec 26, 2025
Price after drop$19.72Ultragenyx share price on Dec 29, 2025
Lead-plaintiff deadlineApril 6, 2026Deadline to seek appointment as lead plaintiff
Toll-free contact1-877-515-1850KSF phone number for affected Ultragenyx investors
Case number26-cv-01097Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al.
Planned participation in three March healthcare investor conferences with CMO presentations.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows mixed reactions: stock dipped on positive Phase 3 data while prior class action headlines produced modest, directionally inconsistent moves. Overall, news-driven moves have been relatively small versus the earlier ~42% drop tied to the failed setrusumab studies described in the lawsuit notice.
Recent Company History
Over the last few months, RARE has issued a range of updates, from an inducement grant of 10,839 RSUs on Mar 16, 2026 to participation in March investor conferences. A key catalyst was positive Phase 3 DTX301 data reported on Mar 12, 2026, yet shares fell 2.25%. Multiple class action–related releases in late February showed only modest price moves, framing today’s notice as part of an ongoing legal backdrop following the setrusumab trial failure.
Key Terms
class action securities lawsuit, securities fraud, Phase 3, Phase III, +4 more
8 terms
class action securities lawsuitfinancial
"notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" ) ... of a class action securities lawsuit."
A class action securities lawsuit is a legal claim brought collectively by a group of investors who say they were harmed by a company’s false or misleading statements, bad accounting, or failure to disclose important facts. It matters to investors because outcomes — settlements, fines, leadership changes or prolonged legal costs — can reduce a company’s cash, damage its reputation and depress the stock price, similar to many neighbors joining one lawsuit that drains a builder’s resources.
securities fraudfinancial
"investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025."
Securities fraud is the illegal act of lying to or misleading investors about the true value or prospects of stocks, bonds or other traded financial instruments — for example by making false statements, hiding key facts, trading on secret information, or artificially moving prices. It matters to investors because it can cause sudden losses, distort fair market prices and undermine trust in markets; think of it as someone rigging a scoreboard so others place bets on the wrong team.
"the Company announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta""
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
Phase IIImedical
"disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab"
A Phase III trial is the late-stage clinical study that tests whether a medical treatment works and is safe in a large group of patients, often comparing it to standard care. Think of it as a final dress rehearsal or full-scale road test before regulators decide on approval; positive or negative results strongly influence a drug maker’s chance to sell the treatment, future revenue, and investment risk.
statistically significanttechnical
"failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates"
"Statistically significant" means that a result or difference observed in data is unlikely to have occurred by chance alone, suggesting there is a real underlying effect. For investors, it indicates that the findings or patterns they see are likely meaningful and not just random noise, helping them make more informed decisions based on reliable information. Think of it as a pattern that is strong enough to stand out clearly from background randomness.
annualized fracture ratesmedical
"failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients"
Annualized fracture rates measure how many bone breaks occur, on average, per patient over the course of one year, standardizing data from studies with different follow-up lengths. Investors care because this metric translates clinical trial results into an easy-to-compare measure of treatment effectiveness and market value—like converting different trip durations into miles per hour so you can fairly compare speed—impacting regulatory approval, adoption, and revenue potential.
Osteogenesis Imperfectamedical
"results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta"
A genetic disorder that makes bones unusually fragile because the body produces faulty or too little of the protein that gives bone its strength; think of bones like a building made from weak bricks rather than strong ones. Investors track it because treatments, diagnostics, or therapies for the condition can create markets, affect clinical trial outcomes, regulatory approvals, and potential revenue for biotech and pharmaceutical companies developing interventions.
lead plaintiffregulatory
"you have until April 6, 2026 to request that the Court appoint you as lead plaintiff"
The lead plaintiff is the representative investor chosen to speak and act on behalf of a group of shareholders in a securities lawsuit. Think of them as the elected spokesperson for a neighborhood when everyone sues a landlord: they coordinate the legal case, make strategic decisions, and negotiate settlements, so their choices can shape outcomes and any recovery that reaches all affected investors. Investors care because the lead plaintiff’s resources and approach can influence the size and speed of any payout and the costs deducted from it.
NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of Ultragenyx who were adversely affected by alleged securities fraud between August 3, 2023 and December 26, 2025. Follow the link below to get more information and be contacted by a member of our team:
CASE DETAILS: On December 26, 2025, the Company announced the "results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta" disclosing that both its Phase III Orbit and Cosmic studies failed to demonstrate that setrusumab triggered a statistically significant reduction in annualized fracture rates for patients with osteogenesis imperfecta, and, as a result the Company "is evaluating its planned operations and will promptly define and implement significant expense reductions." On this news, the price of Ultragenyx's shares fell approximately 42%, from $34.19 per share on December 26, 2025 to $19.72 per share on December 29, 2025.
The case is Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097.
WHAT TO DO? If you invested in Ultragenyx and suffered a loss during the relevant time frame, you have until April 6, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
View original content to download multimedia:https://www.prnewswire.com/news-releases/ultragenyx-pharmaceutical-inc-notice-of-april-6-2026-application-deadline-for-class-action-lawsuit---contact-lewis-kahn-esq-at-kahn-swick--foti-llc-before-application-deadline-302727707.html